argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYGART and VYGART HYTRULO to treat generalized myasthenia gravis (gMG), immune thrombocytopenia (ITP), and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative and ocular gMG, thyroid eye diseases, ITP, myositis, Sjögren's disease, lupus nephropathy, systemic sclerosis, antibody-mediated rejection, and autoimmune encephalitis; empasiprubart for multifocal motor neuropath, CIDP, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome, amyotrophic lateral sclerosis, and spinal muscular atrophy. In addition, the company is also developing ARGX-119, a MuSK agonist to treat congenital myasthenic syndromes and amyotrophic lateral sclerosis; ARGX-109, which targets IL-6 to treat inflammation; ARGX-121 and ARGX 220 that targets the immune system; ARGX-213, which targets FcRn; and ARGX-118, which develops antibodies against Galectin-10, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It has strategic collaborations with OncoVerity, Inc, LEO Pharma A/S, Zai Lab Limited, AbbVie, Inc., Elektrofi, Genmab SE, Chugai Pharmaceutical Co., Ltd., Clayton Foundation, Halozyme Therapeutics, Inc., AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., Lonza Sales AG, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, and IQVIA Ltd. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

argenx SE

In a report released today, Derek Archila from Wells Fargo maintained a Buy rating on Argenx Se, with a price target of $1,291.00. Archila covers t...

Wells Fargo Keeps Their Buy Rating on Argenx Se (ARGX)

In a report released today, Rajan Sharma from Goldman Sachs maintained a Buy rating on arGEN X, with a price target of €885.00. According to TipRan...

arGEN X (0QW0) Receives a Buy from Goldman Sachs

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Gilead Sciences (GILD), Jazz Pharmaceuticals (JAZZ) ...

Wall Street Analysts Are Bullish on Top Healthcare Picks

In a report released today, from Wedbush maintained a Buy rating on Argenx Se, with a price target of $1,000.00. In a report released today, H.C. W...

Argenx Se (ARGX) Gets a Buy from Wedbush

Argenx Se ( ($ARGX) ) has issued an update. On June 3, 2026, Argenx reported new clinical data for VYVGART presented at the EULAR 2026 Congress, sh...

Argenx Showcases Durable VYVGART Benefits in Myositis and Sjogren’s at EULAR 2026

RBC Capital analyst Luca Issi maintained a Buy rating on Argenx Se today and set a price target of $890.00. Issi covers the Healthcare sector, focu...

RBC Capital Sticks to Their Buy Rating for Argenx Se (ARGX)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Roche Holding AG (RHHVF), Cingulate Inc (CING) and A...

Current Quarter	$6.27	Next Quarter	$6.69
Current Year	$26.19	Next Year	$33.52
QoQ Growth	+6.7%	YoY Growth	+28.0%
3Y EPS CAGR	+0.0%	Target Price	$1027.55
Consensus	Buy	Upside	+17.1%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ARGX	$877.72	-1.63%	351.97K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	ARGX	$877.72	-1.6%	351.97K
3
4
5
6

ARGX

ARGX

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get argenx SE Data in Excel

Get argenx SE Data in Excel